Article
GTC featured in OC Business Journal
GTC Expands Cancer Tests to Europe via Partnership By Yuika Yoshida April 7, 2025 Genomic Testing Cooperative (GTC) is expanding into the European market by partnering with
April 16, 2025 12:12 pm
Article
Read More »
Article
BioAI and Genomic Testing Cooperative Announce Strategic Collaboration to Provide AI-Powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications
Manchester, NH – June 25, 2024 – BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology. GTC will become an early technology access member of BioAI’s global ecosystem of clinical laboratories.
June 25, 2024 5:05 am
Article
Τumor-informed vs Tumor-naïve
Liquid biopsies are a rapidly evolving diagnostic technology with numerous labs offering commercially available tests today. Most labs have taken an approach of cell-free (cfDNA)
July 3, 2023 10:36 am
Article
New publication on how cfRNA and AI are advancing LBx
GTC has a new publication in Heliyon titled “The Potential of Cell-Free RNA in Liquid Biopsy: Comprehensive Analysis of Mutation Profile, Chromosomal Abnormalities, and Immune
May 23, 2023 11:37 am
Article
Meet Us at ASH – Happy hour event
ASH is just over a month away. Come meet with the GTC team and its co-op partners at our happy hour event. Download your invitation
November 4, 2022 9:34 am
Article
Case Study: VEXAS Syndrome
Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of
June 8, 2022 11:20 am
Article
What are some of the hematologic manifestations of VEXAS syndrome?
A Man with a Recurrent Left Pleural Effusion In late 2020, a new disease entity that was referred to as VEXAS (vacuoles, E1 enzyme, X-linked,
March 16, 2022 12:28 pm
Article
GTC scientists contribute to major study published in Journal of Clinical Oncology: Prediction of outcome in CLL patients
GTC scientists collaborate with the NIH on a study just published in the Journal of Clinical Oncology. The publication is titled: Prediction of outcome in
October 8, 2020 10:45 am
Article
Genomic Testing Cooperative Aims to Expand Clinical, Commercial NGS Access With Co-Op Model
Jul 23, 2020 | John Gilmore NEW YORK – As part of plans to establish a country-wide network of labs for minimizing the cost of
August 26, 2020 9:20 am
Article
Utilize the first AI software for diagnosing DLBCL
GTC is the first and only diagnostic lab to deploy true artificial intelligence (AI) software for classifications of lymphoma. Do not accept partial results, send
August 5, 2020 11:00 am